Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
17 hedge funds and large institutions have $1.49M invested in Interpace Biosciences, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
2,643% more capital inflows, than outflows
Capital inflows: $2.86M | Capital outflows: $104K
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
7.35% more ownership
Funds ownership: 1.44% → 8.79% (+7.4%)
6% more funds holding
Funds holding: 16 → 17 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.41M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.04M |
| 3 |
Virtu KCG Holdings
New York
|
+$144K |
| 4 |
Wedbush Securities
Los Angeles,
California
|
+$103K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$52K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$61.2K |
| 2 |
JP Morgan Chase
New York
|
-$37K |
| 3 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
-$5K |
| 4 |
BlackRock
New York
|
-$920 |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$20 |
IDXG Hedge Fund Activity: Q2 2017 in Review
17 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q2 2017, worth a combined $1.49M — up 111% from $704K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new IDXG positions and 4 closed out — a net gain of 2 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $1.41M. The largest seller was Morgan Stanley, cutting an estimated $61.2K.
- 17 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q2 2017, up from 16 in Q1 2017.
- Funds reported $1.49M of Interpace Biosciences, Inc. Common Stock stock for Q2 2017, up 111% quarter-over-quarter.
- 6 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q2 2017 and 4 closed out, a net change of +2 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q2 2017 was Susquehanna International Group, an estimated $1.41M added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q2 2017 was Morgan Stanley, an estimated $61.2K sold.
Based on aggregated 13F filings for Q2 2017.